Trial Profile
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Nov 2022
Price :
$35
*
At a glance
- Drugs Lenabasum (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- 14 Nov 2022 Results assessing Efficacy, Safety, and Tolerability of JBT-101/Lenabasum in Systemic Lupus Erythematosus presented at the ACR Convergence 2022
- 09 Aug 2022 According to a Corbus Pharmaceuticals media release, data for the recognized regulatory and clinical endpoints for SLE (BILAG-2004 and the SELENA-SLEDAI) are still pending.; topline data is planned for presentation at an upcoming rheumatology congress.
- 09 Aug 2022 Primary endpoint (Change from Baseline in the 7-Day Average of the Maximum Daily NRS-Pain Score at Day 84) has not been met as per Corbus Pharmaceuticals media release